
Unicycive Therapeutics (UNCY) Stock Forecast & Price Target
Unicycive Therapeutics (UNCY) Analyst Ratings
Bulls say
Unicycive Therapeutics is expected to see positive updates in their quarterly financial results, with modest increases in SG&A balanced by decreases in R&D. The company has also made progress in obtaining FDA approval for their key product OLC, despite last year's CRL. Additionally, they have a potential launch in 3Q 2026 and are actively working on securing reimbursement for OLC. These factors, along with a positive regulatory outlook and a strong focus on addressing unmet medical needs, contribute to our positive outlook on the stock.
Bears say
Unicycive Therapeutics is facing several challenges that could negatively impact its sales potential and valuation. These include potential delays or setbacks in bringing OLC to market, difficulty obtaining reimbursement for the product, and challenges with commercial execution by the Unicycive team. In addition, the company has a significant amount of debt and may need to raise additional capital, which could dilute current shareholders. As a result, the company is not expected to be profitable until 2027, putting it at a disadvantage compared to its competitors.
This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction
Start investing in Unicycive Therapeutics (UNCY)
Order type
Buy in
Order amount
Est. shares
0 shares